Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1979 1
1980 1
1981 1
1983 1
1993 1
1996 2
1997 10
1998 4
1999 1
2000 5
2001 10
2002 6
2003 1
2004 13
2005 7
2006 11
2007 5
2008 8
2009 13
2010 11
2011 10
2012 7
2013 11
2014 7
2015 7
2016 7
2017 8
2018 8
2019 10
2020 11
2021 6
2022 12
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

202 results
Results by year
Filters applied: . Clear all
Page 1
Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer.
Peuker K, Strigli A, Tauriello DVF, Hendricks A, von Schönfels W, Burmeister G, Brosch M, Herrmann A, Krüger S, Nitsche J, Južnić L, Geissler MM, Hiergeist A, Gessner A, Wirbel J, Ponnudurai RP, Tunger A, Wehner R, Stange DE, Weitz J, Aust DE, Baretton GB, Schmitz M, Röcken C, Hampe J, Hinz S, Zeller G, Chavakis T, Schafmayer C, Batlle E, Zeissig S. Peuker K, et al. Among authors: geissler mm. Immunity. 2022 Apr 12;55(4):701-717.e7. doi: 10.1016/j.immuni.2022.03.008. Epub 2022 Mar 31. Immunity. 2022. PMID: 35364006
Erlotinib.
Steins M, Thomas M, Geißler M. Steins M, et al. Among authors: geissler m. Recent Results Cancer Res. 2018;211:1-17. doi: 10.1007/978-3-319-91442-8_1. Recent Results Cancer Res. 2018. PMID: 30069756 Review.
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
Modest DP, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Ricke J, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Geissler M. Modest DP, et al. Among authors: geissler m. J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609637 Clinical Trial.
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Coelho T, et al. Among authors: geissler m. N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760. N Engl J Med. 2013. PMID: 23984729 Free article. Clinical Trial.
Erlotinib.
Steins M, Thomas M, Geissler M. Steins M, et al. Among authors: geissler m. Recent Results Cancer Res. 2014;201:109-23. doi: 10.1007/978-3-642-54490-3_6. Recent Results Cancer Res. 2014. PMID: 24756788 Review.
Erlotinib.
Steins M, Thomas M, Geissler M. Steins M, et al. Among authors: geissler m. Recent Results Cancer Res. 2010;184:21-31. doi: 10.1007/978-3-642-01222-8_2. Recent Results Cancer Res. 2010. PMID: 20072828 Review.
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV. Novello S, et al. Among authors: geissler m. Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5. Ann Oncol. 2022. PMID: 34624497 Free article. Clinical Trial.
Exploring vast microbial epitope spaces.
Geissler MM, Zeissig S. Geissler MM, et al. Immunity. 2022 Oct 11;55(10):1758-1760. doi: 10.1016/j.immuni.2022.09.010. Immunity. 2022. PMID: 36223724
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
Seufferlein T, Uhl W, Kornmann M, Algül H, Friess H, König A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Seufferlein T, et al. Among authors: geissler m. Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7. Ann Oncol. 2023. PMID: 36209981 Clinical Trial.
[From Molecuar to Natural Medicine].
Allgaier HP, Arnold C, Baumert TF, Becker G, Geißler M, Hafkemeyer P, Harder J, Heim MH, Huber R, Kern WV, Mohr L, Moradpour D, Offensperger S, Offensperger WB, Spangenberg HC, Thimme R, Walter E, von Weizsäcker F. Allgaier HP, et al. Among authors: geissler m. Dtsch Med Wochenschr. 2018 Jan;143(1):40-45. doi: 10.1055/s-0043-123263. Epub 2018 Jan 9. Dtsch Med Wochenschr. 2018. PMID: 29316584 German. No abstract available.
202 results